Special Issue

HIV Infection: A Chronic Disease

Message from the Guest Editor

Dear colleagues, HIV infection today still causes thousands of deaths worldwide. ART therapies guarantee a normal life to these children, with some side effects that we need to study deeply. Moreover, vertically acquired HIV produces cultural and social stigma and worries that we are still not able to manage efficiently. I make every day my clinical efforts in treat at 360° my patients, from birth to adults life; for this is very important the collaboration of the pediatrician with the infectious disease specialists, as well as with gynecologists to address the problem of maternity in young HIV- infected women. In this panorama of HIV infection there are still many problems and some topic are yet to be defined:

- HIV and coinfection: clinical and therapeutics interference
- HIV and COVID-19: have we learnt something new about immunodeficiency? Did COVID-19 infection aggravate the acquired immunodeficiency status?
- HIV and parenthood: which possibility can we guarantee to our patients?
- HIV and ART therapies: what's new on drug resistance
- HIV and drug adverse effect
- HIV and social behavior

Guest Editor

Prof. Vania Giacomet

Pediatric Infectious Disease Unit, ASST Fatebenefratelli-Sacco, University of Milan, 20157 Milan, Italy

Deadline for manuscript submissions

closed (30 April 2021)



Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/54140

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms





Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

